Tips & Tricks: GPC/SEC Peak Identification in GPC/SEC - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tips & Tricks: GPC/SEC Peak Identification in GPC/SEC


The Column
Volume 6, Issue 22

Analysing a complex mixture of unknown macromolecules and low molar mass compounds is often challenging in GPC/SEC. A disadvantage of the most commonly used detector, the very universal but unspecific refractive index (RI) detector, is that this detector only provides concentration information and no information about the chemistry. In addition, various positive and negative peaks besides the pure sample peaks in a GPC/SEC run are normal. However, only when the chemical structures of the polymer components are known can sophisticated separation techniques, such as GPC/SEC, liquid adsorption chromatography (LAC) or liquid adsorption chromatography under critical conditions (LACCC) be properly adapted. Also, advanced detection such as on-line light scattering or triple detection requires the knowledge of the chemistry, since these techniques need specific sample related constants (e.g., the refractive index increment dn/dc). Therefore peak identification or substance identification can be very important in GPC/SEC, especially when establishing new methods. There are several possibilities for GPC/SEC users to identify peaks or to learn more about sample chemistry.

Click here for the full article in The Column

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: The Column,
Click here